Jaguar Animal Health
Latest round
- Series A
Last raised
- Feb 2014
Total raised
- $2M
Investors
- 1
About Jaguar Animal Health
Jaguar Animal Health, Inc.Jaguar Animal Health, Inc. is dedicated to the development of plant-based medicines for animal health, particularly for gastrointestinal diseases. Founded in 2013, the company is headquartered in San Francisco, US.02 mn.Jaguar Health specializes in the development and commercialization of plant-based prescription medicines aimed at addressing gastrointestinal (GI) diseases. Their core product, crofelemer, is currently being evaluated in a Phase 3 trial for the preventative treatment of cancer therapy-related diarrhea, demonstrating its therapeutic potential in oncology settings. Additionally, the company supports investigator-initiated proof-of-concept studies of crofelemer for rare diseases such as short bowel syndrome and microvillus inclusion disease. These products are designed to meet unmet medical needs in various regions, including the United States, Europe, and the Middle East/North Africa, with an emphasis on improving patients' quality of life through innovative treatments.Jaguar Health's revenue streams are primarily derived from the sales of its plant-based prescription medicines, focusing on securing partnerships and collaborations for research and product development. Transactions typically occur through direct sales to healthcare providers and institutions that utilize their flagship product, crofelemer, in clinical settings. The company also engages in B2B relationships with pharmaceutical distributors and wholesalers that facilitate the delivery of their products to end-users. Given the focus on innovative GI treatments, pricing structures reflect the specialized nature of the medications, tailored to the needs of healthcare facilities and potential insurance reimbursements. The company aims to enhance its product portfolio, with additional launches in veterinary gastrointestinal treatments expected in the near term. Furthermore, it seeks to expand into new geographic markets, specifically targeting regions in Europe and the Middle East/North Africa by late 2024. The recent merger with Napo Pharmaceuticals will also facilitate additional revenue streams from Mytesi (crofelemer), allowing Jaguar Health to strengthen its market position and enhance its capabilities in addressing veterinary health challenges.
Who invested in Jaguar Animal Health
1 investor across 1 round
See all investors in Jaguar Animal Health
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Feb 5, 2014
Amount
$2M
Investors
Questions about Jaguar Animal Health
Who invested in Jaguar Animal Health?
Jaguar Animal Health has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Jaguar Animal Health raised?
Jaguar Animal Health has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Jaguar Animal Health last raise money?
Jaguar Animal Health's most recent round on record is a Series A, in Feb 2014.
What does Jaguar Animal Health do?
Jaguar Animal Health is a pharmaceuticals company.
Where is Jaguar Animal Health headquartered?
Jaguar Animal Health is headquartered in San Francisco, US.
Which VCs invest in companies like Jaguar Animal Health?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Jaguar Animal Health's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Jaguar Animal Health? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.